In a guest post in the Global Health Technologies Coalition’s “Breakthroughs” blog, Kari Stoever, vice president of external affairs at Aeras, “writes about European support for new vaccines against tuberculosis (TB).” She notes, “Europe is a major contributor to the development of vaccines globally, with as much as 75 percent of the global TB vaccine portfolio either originating in Europe or being developed in partnership with European public or private organizations.” She highlights a recent “€25 million (approximately $34 million) call for proposals to accelerate the development of new TB vaccines” by the E.U., which she says “comes as an important new collaboration between European funders and a global network of researchers is forming” (12/17).